About Amarin Corporation plc
https://www.amarincorp.comAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates.
CEO
Aaron D. Berg
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-11 | Reverse | 1:20 |
| 2008-01-18 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 4
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
OPPENHEIMERFUNDS, INC.
Shares:7.85M
Value:$117.89M
BLACKROCK FUND ADVISORS
Shares:3.5M
Value:$52.56M
LONGITUDE (CAYMAN) LTD.
Shares:1.62M
Value:$24.32M
Summary
Showing Top 3 of 178
About Amarin Corporation plc
https://www.amarincorp.comAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $48.56M ▼ | $23.91M ▼ | $-7.74M ▲ | -15.94% ▲ | $-0.02 ▲ | $-6.49M ▼ |
| Q2-2025 | $72.74M ▲ | $66.35M ▲ | $-14.14M ▲ | -19.44% ▲ | $-0.03 ▲ | $7.5M ▲ |
| Q1-2025 | $42.02M ▼ | $41.88M ▼ | $-15.7M ▲ | -37.36% ▲ | $-0.8 ▼ | $-16.02M ▲ |
| Q4-2024 | $62.31M ▲ | $42.95M ▲ | $-48.62M ▼ | -78.03% ▼ | $-0.12 ▼ | $-37.18M ▼ |
| Q3-2024 | $42.3M | $41.44M | $-25.13M | -59.42% | $-0.06 | $-24.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $286.59M ▼ | $659.81M ▼ | $200.92M ▼ | $458.89M ▼ |
| Q2-2025 | $298.7M ▲ | $670.13M ▲ | $205.2M ▲ | $464.92M ▼ |
| Q1-2025 | $281.79M ▼ | $655.68M ▼ | $181.99M ▼ | $473.69M ▼ |
| Q4-2024 | $294.22M ▼ | $685.35M ▼ | $199.17M ▼ | $486.18M ▼ |
| Q3-2024 | $305.73M | $750.62M | $219.24M | $531.38M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.69M ▲ | $-12.76M ▼ | $-12.29M ▼ | $-240K ▲ | $-25.07M ▼ | $-12.76M ▼ |
| Q2-2025 | $-14.14M ▲ | $16.61M ▲ | $12.41M ▲ | $-663K ▲ | $28.35M ▲ | $16.61M ▲ |
| Q1-2025 | $-15.7M ▲ | $-12.46M ▲ | $12.06M ▲ | $-1.12M ▼ | $-1.51M ▲ | $-12.46M ▲ |
| Q4-2024 | $-48.17M ▼ | $-13.24M ▼ | $-22.75M ▲ | $22.95K ▲ | $-36.13M ▲ | $-13.24M ▼ |
| Q3-2024 | $-25.39M | $-2.43M | $-56.67M | $-74.13K | $-58.98M | $-2.43M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Licensing And Royalty | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
 Product | $60.00M ▲ | $40.00M ▼ | $50.00M ▲ | $50.00M ▲ |
Revenue by Geography
| Region | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|
 Europe | $10.00M ▲ | $0 ▼ | $10.00M ▲ |
 UNITED STATES | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ |
CEO
Aaron D. Berg
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-04-11 | Reverse | 1:20 |
| 2008-01-18 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 4
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
OPPENHEIMERFUNDS, INC.
Shares:7.85M
Value:$117.89M
BLACKROCK FUND ADVISORS
Shares:3.5M
Value:$52.56M
LONGITUDE (CAYMAN) LTD.
Shares:1.62M
Value:$24.32M
Summary
Showing Top 3 of 178